Buscar
Immuneering Corp
IMRXAñadir a la lista de seguimiento
4.130USD
-0.100-2.36%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
267.20MCap. mercado
PérdidaP/E TTM
Más Datos de Immuneering Corp Compañía
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Información de Immuneering Corp
Símbolo de cotizaciónIMRX
Nombre de la empresaImmuneering Corp
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoZeskind (Benjamin J)
Número de empleados66
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección245 Main Street, Second Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16175008080
Sitio Webhttps://immuneering.com/
Símbolo de cotizaciónIMRX
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoZeskind (Benjamin J)
Ejecutivos de Immuneering Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.07%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
74.53K
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
29.60K
+12.26%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.53K
+1.09%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Dr. Brett Hall, Ph.D.
Dr. Brett Hall, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Michael D. Bookman
Mr. Michael D. Bookman
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Mr. Peter E. Feinberg
Mr. Peter E. Feinberg
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.07%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
74.53K
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
29.60K
+12.26%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.53K
+1.09%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immuneering Corp?
Los cinco principales accionistas de Immuneering Corp son: Dr. Benjamin J. (Ben) Zeskind, Ph.D.
¿Cuántas instituciones poseen acciones de Immuneering Corp (IMRX)?
A fecha de 2026Q1, 195 instituciones poseen acciones de Immuneering Corp, con un valor de mercado combinado de aproximadamente 30.53M, lo que representa el 47.18% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1149285.00.